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A comprehensive platform for  
the analysis of ubiquitin-like 
protein modifications using  
in vivo biotinylation
Lucia Pirone1, Wendy Xolalpa1,†, Jón Otti Sigurðsson2, Juanma Ramirez3, Coralia Pérez1, 
Monika González1, Ainara Ruiz de Sabando1, Félix Elortza1, Manuel S. Rodriguez4, 
Ugo Mayor3,5, Jesper V. Olsen2, Rosa Barrio1 & James D. Sutherland1
Post-translational modification by ubiquitin and ubiquitin-like proteins (UbLs) is fundamental for 
maintaining protein homeostasis. Efficient isolation of UbL conjugates is hampered by multiple 
factors, including cost and specificity of reagents, removal of UbLs by proteases, distinguishing UbL 
conjugates from interactors, and low quantities of modified substrates. Here we describe bioUbLs, 
a comprehensive set of tools for studying modifications in Drosophila and mammals, based on 
multicistronic expression and in vivo biotinylation using the E. coli biotin protein ligase BirA. While the 
bioUbLs allow rapid validation of UbL conjugation for exogenous or endogenous proteins, the single 
vector approach can facilitate biotinylation of most proteins of interest. Purification under denaturing 
conditions inactivates deconjugating enzymes and stringent washes remove UbL interactors and non-
specific background. We demonstrate the utility of the method in Drosophila cells and transgenic flies, 
identifying an extensive set of putative SUMOylated proteins in both cases. For mammalian cells, we 
show conjugation and localization for many different UbLs, with the identification of novel potential 
substrates for UFM1. Ease of use and the flexibility to modify existing vectors will make the bioUbL 
system a powerful complement to existing strategies for studying this important mode of protein 
regulation.
Protein homeostasis contributes to the natural equilibrium within the cells, and its disruption is often the cause 
or consequence of multiple diseases. The balance is achieved in many instances through post-translational mod-
ifications (PTMs) by ubiquitin (Ub) and ubiquitin-like (UbL) proteins, controlling the function, localization 
or stability of target proteins. Ub is a 76-aa polypeptide that can modify target proteins through the process of 
ubiquitination, the attachment of an activated Ub moiety through a C-terminal glycine to a lysine or selected 
other residues in the target substrate1. The process involves the activation of Ub by an E1 enzyme, the transfer 
of the active moiety to an E2 conjugating enzyme and, in many instances, the cooperation of an E3 ligase that 
binds both the E2-bound Ub and the substrate. Deubiquitinases (DUBs) can revert the modification, conferring 
flexibility and regulation to the process2. Although most commonly associated to protein degradation by the pro-
teasome, more recently ubiquitination has been related to a wide variety of cellular processes, including protein 
trafficking and DNA repair among others. Ub itself can be ubiquitinated in any of its seven lysines or the initiating 
methionine, forming chains that can adopt different conformations. This constitutes a complex code that can lead 
modified proteins to different outcomes3.
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Ub is the most conserved protein found in all eukaryotes. Approximately 20 proteins have been identified 
that are related to Ub, known as UbLs4,5. Some have recognizable sequence homology with Ub, while more 
divergent UbLs share similar structural features. All of them share the beta-grasp fold characteristic of Ub and 
all participate in processes similar to ubiquitination, suggesting a common ancestry to this family of proteins4. 
Among the UbLs, the one that shares the highest homology with Ub is NEDD8 (NEural precursor cell-expressed, 
Developmentally Downregulated 8). While thousands of Ub targets have been identified, the reported number 
of NEDDylated proteins is lower. Among those, the cullins are RING E3 ligases that link NEDDylation to the 
ubiquitination of a wide spectrum of targets that participate in many cellular processes6.
The Small Ub-like MOdifier, SUMO, is one of the most studied UbLs7. In vertebrates, there are five differ-
ent SUMO genes, SUMO1-5. SUMO2 and SUMO3 are almost identical and share 50% identity with SUMO1. 
All SUMOs use the same E1 and E2 enzymes in the process of SUMOylation, and can participate in forming 
polySUMO or mixed Ub-SUMO chains. SUMO4 seems to be a pseudogene or it is not processed8,9, while the 
recently reported SUMO5 shows tissue-specificity and participates in nuclear body formation10. In yeast and 
Drosophila there is a single SUMO homologue, Smt3. SUMOylation has been related to transcriptional repression 
and response to cellular stresses such as DNA damage.
Other UbLs are less well characterized. ISG15 (Interferon-Stimulated Gene 15) is induced by interferons 
secreted by virus-infected cells and participates in the anti-viral immune response11. FAT10 (HLA-F Adjacent 
Transcript 10, also called UBD) is expressed in immune cells and can also be induced in other cell types by inter-
feron gamma or TNF-alpha. FAT10 can mediate Ub-independent proteasomal degradation12,13. Neither ISG15 
nor FAT10 are conserved in lower eukaryotes. Both are composed of two UbL modules, whereas other UbLs have 
a single module. The Ub-Fold Modifier-1, UFM1, is conserved in metazoans and plants. It has a role in erythroid 
and megakaryocyte development, homeostasis of the endoplasmic reticulum (ER) and vesicle trafficking14. ATG8 
and ATG12 are involved in the regulation of autophagy. ATG8 is a lipid modifier that is conjugated to phos-
phatidylethanolamine and participates in autophagosome biogenesis. There are 6 ATG8 orthologues in humans, 
classified as GABARAP1-2 and MAP1LC3A-B. ATG12 is conjugated to at least one other protein in the outer part 
of the autophagosome membrane, where this complex acts as the E3 ligase for Atg815. FAU (Finkel-Biskis-Reilly 
murine sarcoma virus, ubiquitously expressed) is synthesized as a fusion protein with the ribosomal protein S30. 
In macrophages, FAU inhibits lipopolysaccharide-induced signalling and phagocytosis, having an immunoreg-
ulatory role16. The Ub Related Modifier 1, URM1, is conserved in eukaryotes and its structure resembles that of 
ancient prokaryotic sulfur carriers. Sulfur donors involved in the biosynthetic pathway of thiamine (vitamin B1) 
and molybdopterin (MPT) in prokaryotes, ThiS and MoaD, have a certain homology with Ub and contain a 
beta-grasp fold. Therefore, URM1 might represent a bridge between the prokaryotic sulfur carriers and the eukar-
yotic UbLs17.
Given the variety of UbLs that exist, the different types of monotypic chains that they can potentially form, 
and that there can even exist hybrid chains containing different types of UbLs, a complex UbL code may underlie 
numerous biological and cellular processes. This has prompted researchers to develop different systems to iso-
late UbL-modified proteins using cultured cells, model organisms, and clinical tissue samples. Most approaches 
are modelled on those successfully used to study Ub, such as using epitope-tagged Ub (with 6xHIS or HA 
tags). Approaches to study endogenous Ub modifications include monoclonal antibodies directed against the 
di-Gly residual peptide found on Ub substrates after deubiquitination, or molecular traps formed from tandem 
Ub-binding domains (TUBEs)18,19.
Although more challenging due to its low abundance, SUMOylation has been extensively studied using sim-
ilar approaches. Different single or double epitope tags fused to the N-terminus of SUMO have been used to 
enrich for conjugates. Examples include 6x-10xHIS, FLAG, Myc, 6xHIS-FLAG, 6xHIS-HA, FLAG-TEV and 
ProtA-TEV-CBP for use in cell culture as well as transgenic organisms20. DeSUMOylating activity is high in cell 
lysates, so chemical inhibitors or ideally denaturing conditions are used during capture of conjugates to preserve 
SUMOylation. Using exogenous tagged SUMO also allows the use of SUMO mutants that may be defective in 
chain formation (e.g. SUMO2-K11R) or optimized for mass spectrometry analysis (MS; e.g. SUMO2-T90R)21. 
To analyse endogenous SUMO conjugates, a method called PRISM has been developed for the identification of 
SUMOylation sites based on the chemical blockade of all free lysines, followed by treatment with a SUMO-specific 
protease and subsequent biotin-tagging of ‘freed’ lysines and identification by high-resolution MS22. Monoclonal 
antibodies with mapped epitopes in SUMO1 or SUMO2/3 allow the identification of SUMOylated pro-
teins in endogenous conditions23. Finally, SUMO-traps have been developed to enrich and identify poly- or 
multi-monoSUMOylated proteins24,25. Identification of other UbL-modifications has been performed using exog-
enous epitope-tagged versions or using antibodies to detect endogenous substrates26–31.
Variations between these approaches can identify different targets due to diverse levels of stringency, solubility, 
expression levels, and antibody types and their affinities. Furthermore, antibody and molecular trap approaches 
are ideal but require additional expertise and expense for affinity resins. Using an in vivo biotinylation approach, 
it was previously demonstrated that a short N-terminal epitope (Bio or AviTag)32 on Ub is efficiently biotinylated 
in cultured cells and in living organisms (flies/mice) by using the E. coli BirA enzyme, and that biotinylated Ub 
(bioUb) is incorporated efficiently into substrates33,34. Lysis under denaturing conditions allows inactivation of 
UbL isopeptidases and the high affinity biotin-streptavidin interaction allows stringent washes, yielding pure 
UbL-modified proteins with almost no background from non-covalent interactors and non-specific contami-
nants. Here, using a modular multicistronic expression platform35, we have generated a set of tools to study each 
UbL modification under stringent conditions, suitable for MS or validation by Western blotting, in an accessible 
and affordable way. We applied the system to various UbL modifications in cell culture and in vivo, identifying 
known and potentially novel substrates. The bioUbL system can complement existing tools to study UbL modifi-
cations to understand their diversity, regulation, and roles in biological systems.
www.nature.com/scientificreports/
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Results and Discussion
Generation of the bioUbL system in multicistronic vectors. When applying the BirA/Bio tagging 
system to other UbLs, we modelled the initial vectors on the bioUb-BirA fusion, which relied on the capac-
ity of endogenous DUBs to process the tandem bioUb-BirA precursor for the separation of the bioUb and the 
biotinylating enzyme33,34. However, when this design was attempted for SUMO, a large proportion remained 
unprocessed, perhaps due to failure of endogenous SUMO proteases to access the cleavage site. We reasoned that 
co-expression of bioUbLs and BirA separately could improve this, using a multicistronic vector platform35. The 
Ac5-STABLE2 vector encodes three ORFs separated by viral 2A sequences, and were designed to allow modular 
exchange of the promoter and ORF elements. For the first ORF, we placed the biotinylation-target peptide (Bio) 
followed by sites to insert UbL cassettes. For the second ORF, we inserted BirA, encoding the enzyme that trans-
fers biotin to the Bio epitope. To enhance expression, in some cases a human codon-optimized version was used 
(BirAopt)36. For the third ORF, we inserted cassettes to allow stable cell line selection (e.g. puro, puromycin resist-
ant cassette) or selection with either drugs or fluorescence or both (GFPpuro, GFP-puro fusion protein). Also, in 
some cases the third ORF position was exchanged for the respective E2 conjugating enzyme for the UbL being 
studied, which enhanced the recovery of bioUbL conjugates. The convenience to express the respective E2 along 
with the bioUbL should be analysed with caution, as it will be discussed in the Conclusion.
The resulting bioUbL-2A-BirAopt (with puro, GFPpuro, or E2 conjugase; see Supplementary Data S1 for a 
summary of the vectors generated) is self-processed via 2A sequences (Fig. 1A, step 1), the BirA enzyme rec-
ognizes the Bio sequence (step 2), and transfers biotin to the lysine within the Bio sequence (step 3). The small 
C-terminal 2A remnant is removed during the activation step by endogenous UbL isopeptidases and, through 
action of the respective E2 conjugases and E3 ligases, the resulting bioUbL is incorporated into protein targets 
(X, Y, step 4). Modified proteins are purified by streptavidin-based affinity chromatography (step 5) and analysed 
Figure 1. Isolation and identification of bioSmt3 conjugates in Drosophila cultured cells. (A) Schematic 
representation of the bioUbL strategy. See text for details. (B) Up: schematic representation of the bioUbL 
vectors for Drosophila cells. Left: the blot shows the enrichment in bioSmt3 conjugates in the elution panel using 
anti-biotin antibodies (lane 4; bracket). Arrowhead indicates free bioSmt3 in lane 4. Right: top twenty bioSmt3-
modified proteins based on raw intensity. (C,D) bioSmt3 (pAc510x-bioSmt3-Lwr) visualized with fluorescently 
labeled streptavidin (D) localizes in a similar way than the endogenous Smt3 in S2R+ cells (C). Nuclei were 
marked with DAPI (blue). Green and red channels are shown independently in black and white (C’, D’).  
(E) GO analysis for biological process, cellular component and molecular function of the selected bioSmt3-
conjugated protein set (n = 1054).
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by Western blot or MS (step 6). Importantly, lysis and pulldown are performed in denaturing conditions that 
inactivate UbL isopeptidases, selecting for recovery of true covalent UbL conjugates, while non-covalent UbL 
interactors are reduced. Since the components are genetically encoded, the system can be applied in both cell 
culture and transgenic organisms.
bioUbL vectors for the analysis of PTMs in insect cells. As a proof of concept, to study UbLs dif-
ferent than Ub using the in vivo biotinylation approach, we chose to isolate and identify SUMOylated proteins 
in Drosophila cultured cells. Drosophila S2R+ cells were transfected with the Ac5-bioSmt3-Lwr vector or with 
Ac5-FC-GP vector as a control, which contains Flag-Cherry instead of bioSmt3. The vectors were appropriately 
expressed in cells (Supplementary Fig. S1). After pulldown we saw a notable enrichment of biotinylated proteins 
in the sample (Fig. 1B), as well as a prominent band corresponding to the properly processed bioSmt3 fusion.
Drosophila Smt3 localization is mainly nuclear and, as in the case of the SUMO mammalian homologs, Smt3 
concentrates into discrete subnuclear domains (Fig. 1C). To confirm the localization of the biotin-conjugation 
system, we analysed bioSmt3 in the cells using streptavidin conjugated to a fluorescent dye (Fig. 1D). The compar-
ison of the immunofluorescence experiments revealed that bioSmt3 localized in a way similar to the endogenous 
Smt3. In both cases, the proteins were mainly nuclear and localized in nuclear bodies, suggesting the proper 
subnuclear accumulation of the bioSUMOylated targets.
Compared to ubiquitination, modification by SUMO occurs at lower levels in cells in response to defined 
stimuli. For a particular target (which might be weakly expressed) only a small proportion of the cellular pool 
may get SUMOylated. We reasoned that supplying Lesswright (Lwr), the Drosophila homolog of SUMO E2 conju-
gase along with bioSmt3 (which must compete with endogenous Smt3) would allow detection of more conjugates 
while using less cellular lysate. To do this, we replaced the selectable marker GFPpuro by lwr. While we observed 
an appreciable increase in bioSmt3 conjugates (Supplementary Fig. S1), we caution that exogenous E2 expression 
might produce non-physiological SUMO modifications (see Conclusions). To further augment expression levels, 
we modified the Ac5 promoter to include 10 copies of the Upstream Activation Sequence, UAS, just before the 
transcriptional start site. This sequence is recognized by the yeast transcriptional activator Gal4. In the absence 
of Gal4, this modified Ac5 drives expression at lower levels than unmodified Ac5, but in the presence of Gal4, 
bioSmt3 levels were significantly higher. S2R+ cells were transfected with the Ac510x-bioSmt3-Lwr vector, or with 
Ac510x-FC-Lwr as a control, in presence or absence of the pAc5-Gal4 vector. After the pulldown, total protein 
eluates were resolved on a SDS-PAGE and analysed by MS. We identified 1341 putative SUMOylated proteins, 
of which 1054, corresponding to 1042 different genes, were selected based on an 4:1 intensity ratio between the 
experimental samples and the controls (see Methods; Supplementary Data S2; Supplementary Fig. S2).
The Gene Ontology (GO) analysis revealed the enrichment of four biological process categories: develop-
ment, component organization, gene expression or localization and transport (Fig. 1E, Supplementary Data S2). 
The majority of the proteins were localized in the nucleus, including proteins associated to the chromosomes, 
nucleolus or nuclear envelope. Cytoplasmic proteins were enriched for those classified as cytoskeletal and protein 
complex components. With respect to molecular function, we found enrichment of proteins that regulate gene 
expression, considered to be the main function of cellular SUMOylation, but also binding proteins (DNA, RNA, 
protein), underlining a role for SUMO in forming and regulating higher-order complexes.
Most of the identified proteins are functionally related, as revealed by the STRING analysis of interconnected 
networks (Supplementary Fig. S1). Cytoscape MCODE analysis showed 26 interaction clusters that confirm the 
implication in gene expression regulation of the identified SUMO targets (transcription, RNA processing and 
transport, splicing, translation), as well as vesicle-mediated transport, proteasome-mediated Ub-dependent pro-
tein catabolic process, or cell cycle (Supplementary Data S2).
549 proteins (52%) of the proteins found in S2 cells were found previously SUMOylated in other Drosophila 
experiments done using different systems and developmental stages: Drosophila embryos, 37%37 and immune 
challenged S2 cells, 46%38 (Supplementary Fig. S1). This is a substantial overlap considering the different exper-
imental settings among studies (whole embryos versus cultured cells, unstimulated versus stimulated cells). 
Interestingly, this percentage of overlap is lower when we compare our list with the identified targets of bioUb in 
either whole embryos or adult eyes39, supporting the specificity of the bioSmt3 system.
Among the 20 bioSmt3-conjugates that showed highest intensities (all absent from control samples; 
Supplementary Data S2), some are involved in modulation of gene expression, involving transcription regula-
tion (Pontin, Pont; CG7839; CG2982), translation initiation (Adam), polyadenylation (Symplekin, Sym), RNA 
binding/processing (CG11123; Nucleolar protein at 60B, Nop60B) and splicing (small ribonucleoprotein parti-
cle U1 subunit 70 K, snRNP-U1-70K). Others have been linked to nuclear functions, such as heterochromatic 
centromere and chromosomal segregation (Proliferation disrupter, Prod), mitosis (Inner centromere protein, 
Incenp) or components of the nuclear envelope (Otefin, Ote). In the cytoplasm, represented functions include 
transport and trafficking (Short wing, Sw; VAMP-associated protein of 33 kDa orthologue A, Vap-33A) and pro-
tein folding (Tetratricopeptide repeat protein 2, Tpr2). Among those 20, 18 were previously identified as targets of 
SUMOylation (Supplementary Data S2)37,38. In addition, the human homologues of 9 of them were also reported 
to be SUMOylated (UBE21, snRNP-U1-70K, Pont, CG7839, Sym, CG11123, Vap-33A, Nop60B and Adam), sug-
gesting a conserved role for SUMOylation in the function of these proteins.
In addition to Smt3, the Drosophila genome encodes other UbL proteins. These include single homologs of 
NEDD8 (Nedd8), UFM1 (CG34191), and URM1 (CG33276). These genes were used to create bioUbL versions 
and expressed in S2R+ cells (Supplementary Data S1) and expression was confirmed in S2R+ cells. Together 
with bioUb-BirA (adapted from UAS-bioUb-BirA)33,34, these vectors will facilitate analysis of any Ub- or 
UbL-modification in Drosophila cells.
www.nature.com/scientificreports/
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Validation of bioSmt3-conjugates in Drosophila cells. In order to validate our SUMOylation results, 
we chose Ote, Kugelkern (Kuk) and Bocksbeutel (Bocks), all components of the nuclear envelope, which is a 
structure enriched for SUMOylated proteins40–42 and is a described GO category represented by 34 MS hits in 
our list (Supplementary Data S2). Twinstar (Tsr) is the Drosophila orthologue of the actin destabilizing factor 
cofilin. Previous work has demonstrated SUMOylation of human cofilin43,44. Interestingly, we note that one of 
the identified SUMOylation sites of human cofilin (K13) overlaps with its reported nuclear export sequence 
(VIKVFNDMKV)45, which might have important consequences on localization for a small protein like Tsr 
(17 kDa). Tagged versions of these proteins (GFP- or FLAG-) were expressed in S2R+ cells, with and without 
bioSmt3. After the NeutrAvidin pulldowns, Western blots revealed the SUMOylated forms in the elution panels 
only in presence of bioSmt3 (arrowheads in Fig. 2A). Endogenous tubulin was used as a control for the input.
Despite the small proportion of SUMOylated fraction in the general pool of a given protein, we were able 
to validate bioSmt3 conjugation to some endogenous proteins by using available antibodies (Fig. 2B). Three of 
the validated proteins have been previously identified as SUMOylated proteins: Ultraspiracle (Usp), a nuclear 
receptor involved in steroid signalling46, the transcription factor Osa37,47, the intermediate filament Lamin (Lam, 
also a key nuclear envelope component)38 and the eukaryotic initiation factor 4E (eIF-4E)48. One of the validated 
proteins was not previously described to be SUMOylated in Drosophila, the Glutathione S-transferase involved 
in axonogenesis Failed axon connections (Fax), and thus is the first Fax homolog to be identified as a target of 
SUMOylation.
In vivo application of bioSmt3 in transgenic Drosophila. We applied the bioUbL technology in vivo 
by generating transgenic flies expressing the transgene bioSmt3 (Fig. 3A). To test the functionality of the bioSmt3 
transgene in vivo, we analysed its capacity to rescue the silencing of endogenous smt3 in steroidogenic tissues at 
larval stages. Tissue-specific knockdown of smt3 in the prothorathic gland (PG) blocks development at the end of 
larval stages due to a reduction in the steroid levels49,50. This is achieved using a PG-specific GAL4 driver, together 
with UAS-Smt3 RNAi (hereinafter called smt3i). Interestingly, by introducing an RNAi-resistant bioSmt3 trans-
gene in the smt3i background, larvae underwent normal metamorphosis and generated fertile adults (Fig. 3B). 
This indicates that bioSmt3 can complement at least this specific role for SUMOylation during development, 
which may also be the case in other tissues. Importantly, by increasing the bioSmt3/endogenous-Smt3 ratio, the 
chances of recovering rare bioSmt3 conjugates were increased.
We analysed the subcellular distribution of bioSmt3 conjugates in vivo by using fluorescent streptavidin 
in salivary glands from larvae expressing bioSmt3 (hs-Gal4 > UAS-smt3i, p-bioSmt3) or from control larvae 
(hs-Gal4 > UAS-GFP). Larval food was enriched with biotin. After using heat shock (hs) at 37 °C to both activate 
Gal4 and stimulate SUMOylation, we observed the accumulation of bioSmt3 in nuclear bodies, most likely conju-
gated to proteins (Fig. 3C–F). The biotinylated proteins showed a pattern similar to that observed for endogenous 
Smt3 using antibodies.
For the MS experiments, we collected larvae of hs-Gal4 > UAS-Smt3i, p-bioSmt3 or hs-Gal4 > UAS-Smt3i, 
pUAS-BirAopt genotypes. The E2 conjugase Lwr was not exogenously expressed in these experiments. To enrich 
the proportion of proliferating tissues, which exhibit a higher abundance of SUMOylated proteins51, we dis-
sected and processed the anterior part of the larval body where the brain and most of the imaginal discs are 
located. After pulldown, we confirmed the enrichment of bioSmt3 conjugates (Fig. 3A). Protein eluates were 
resolved on SDS-PAGE and analysed by MS. We identified 251 proteins as putative SUMOylation targets 
in vivo (Supplementary Data S3, Supplementary Fig. S3), of which 140 were selected on the basis of a 4:1 intensity 
increase over controls.
The GO analysis (Fig. 3G) revealed common terms with the analysis in cultured cells, such as gene expression, 
translation or RNA, with a higher proportion of proteins localized in the cytoplasm, with the categories of lipid 
particle or cytoskeleton organization being strongly represented. The STRING analysis revealed a network of pro-
teins, where 10 clusters could be identified (Supplementary Fig. S4, Supplementary Data S3). Among those, the 
most prominent is associated to the GO term translation, followed by others such as microtubule cytoskeleton, 
proteasome-mediated Ub-dependent protein catabolic process, chromatin assembly or disassembly or protein 
folding, among others. Some of the clusters reflect terms related to the methodology used in this experiment, such 
as the heat response used to induce expression and SUMOylation, or substrate adhesion, perhaps overrepresented 
due to the presence of the salivary glands in the lysed tissues. Approximately 50% of the proteins identified in vivo 
were also present in the list of bioSUMOylated proteins obtained from cultured cells and 34 or 37% were present 
in the lists of SUMOylated protein identified in Drosophila embryos or immune challenged S2 cells, respectively 
(Supplementary Fig. S4)37,38.
Among the 20 best-scoring bioSmt3 conjugates (Supplementary Data S3), we found parallels to our S2R+ 
dataset, for example proteins involved in different aspects of gene regulation, as chromatin and transcription 
(Histones His3.3A and His2B, CG7839), mRNA polyadenylation (Protein 1 of cleavage and polyadenylation fac-
tor 1, Pcf11) and translation (Eukaryotic initiation factor 4a, eIF-4a, and eIF4AIII), as well as cytoskeleton and 
protein trafficking (TER94, CG7852, Tubulins betaTub60D and betaTub85D, or Wings up A, WupA). 70% of 
these proteins (14/20) were identified as SUMOylated either previously or in this work in S2R+ cells. Also, the 
human homologues of many (17/20) have been independently identified as SUMO targets. CG42671, CG30069 
and WupA were not previously identified as Smt3 targets. The human homolog of WupA the muscle-enriched 
TNNI2 (troponin I2, fast skeletal type) has never been identified as a possibly SUMOylated protein, which may 
reflect that most SUMO proteomics studies are done in cells rather than using whole tissues.
The notable difference in the number of putative SUMO conjugates when comparing the MS list obtained 
from S2R+ cells (1054) with the list obtained from larvae (140), is likely due to experimental differences. For 
example, cells yield better and more uniform lysates than tissues, biotin availability in vivo may be limiting and 
a lower quantity of in vivo material was processed compared to cells. Also, in flies we used RNAi to increase the 
www.nature.com/scientificreports/
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Figure 2. Validation of bioSmt3-modified proteins. (A) Anti-Flag or anti-GFP Western blot of pulldowns 
performed in S2R+ cells transfected respectively with GFP-kuk, GFP-Ote, GFP-bocks or Flag-Cherry-tsr, together 
with pAc5-GAL4 and pAc510x-bioSmt3-Lwr (bioSmt3) (+ ) or Ac510x-FC-Lwr (− ) as control. In the elution panels, 
arrowheads indicate the modified forms of each protein. Tubulin was used as a loading control. Molecular weight 
markers are shown to the left. (B) Western blot of pulldowns performed in S2R+ cells. Specific antibodies against 
endogenous proteins were used: Ultraspiracle (Usp), the Trithorax group protein Osa, Eukaryotic initiation factor 
4E (eIF-4E), Failed axon connections (Fax) and Lamin (Lam). In elutions, arrowheads indicate the modified forms 
of the respective proteins. Molecular weight markers are shown to the left.
www.nature.com/scientificreports/
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bioSmt3/wild-type Smt3 ratio, while in S2R+ cells, we co-expressed the E2 conjugase lwr along with bioSmt3 to 
enhance the process of SUMO conjugation. These aspects might affect the yield of SUMOylated proteins in both 
cases and likely requires optimization for specific applications. Nonetheless, our results show that the bioSmt3 
system can be efficiently applied to identify potential SUMOylated proteins in cultured cells and in vivo (Figs 1 
and 3; Supplementary Data S2, S3).
bioUbL vectors for the analysis of PTMs in mammalian cells. Encouraged by the Drosophila 
results, we turned to mammalian cells to explore whether the system could work equally well and to broaden 
its applications. The modularity of the pAc5-STABLE2-neo vector facilitated the switch from the insect-specific 
promoter Ac5 to the versatile mammalian promoter CAG (Fig. 4A). We substituted the Drosophila smt3 
gene with the following mammalian UbLs: Ub, NEDD8, SUMO1-4, FAT10, ISG15, UFM1, FAU, and URM1 
(Supplementary Data S1). All of these UbLs are thought to conjugate to protein targets through C-terminal gly-
cine(s). Vectors expressing the autophagy-related ATG12 and ATG8 family (GABARAPs and LC3s) were also 
constructed, although these UbLs are thought to modify lipids more than proteins. Some variants of UbLs were 
also cloned (Supplementary Data S1). In most cases, the vectors carry a GFPpuro cassette to allow drug- or 
fluorescence-based selection, although other cassettes (resistance to puromycin, blasticidin, hygromycin) are pos-
sible. In some cases, the selection cassette is exchanged for the corresponding E2 enzyme to increase the efficiency 
of conjugation or address enzyme specificity (Fig. 4A). Using the modular architecture, other combinations could 
Figure 3. In vivo isolation and identification of bioSmt3 conjugates. (A) Up, schematic representation of the 
bioSmt3 vector used for Drosophila transgenesis. Down, the blot shows the enrichment of bioSmt3 conjugates 
in the elution panel using anti-biotin antibodies (lane 4, bracket; strain used: hs-Gal4; UAS-bioSmt3). Asterisks 
indicate the three known endogenously biotinylated proteins in Drosophila. (B) BioSmt3 can substitute for 
endogenous Smt3. Left, larvae silenced for smt3 in the PG, arrested in development at the end of L3 larval stage. 
Right, the developmental arrest is rescued by the expression of bioSmt3 in the same genetic background.  
(C–F). Confocal pictures of cells of the salivary glands of larvae expressing bioSmt3 (E,F) or GFP (C,D). 
bioSmt3 is detected by fluorescently-labeled streptavidin. Heat treatment (37 °C) increased the bioSmt3-positive 
bodies. (G) GO analysis for biological process, cellular component and molecular function of the selected 140 
bioSmt3-conjugated proteins.
www.nature.com/scientificreports/
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Figure 4. Isolation and localization of bioUbL-conjugates in mammalian cells. (A) Schematic representation 
of the bioUbL plasmid collection. (B) BioUbL-conjugates revealed by anti-biotin Western blot. Pulldowns were 
performed in parallel using HEK 293FT cells expressing the different bioUbLs. Conjugates are indicated with a 
bracket. Asterisks indicate endogenously biotinylated proteins. Arrowheads indicate free bioUbLs. Molecular 
weight markers are shown to the left. (C–J) Cellular distribution of different bioUbLs. U2OS cells transfected 
with plasmids expressing the indicated bioUbLs (D–J) or BirA alone as a control (C). Conjugates are visualized 
using fluorescently-labeled streptavidin. (K) White nuclear bodies (white arrowheads indicate two examples) 
reflect the colocalization of bioSUMO1 (purple) with YFP-PML (green). Yellow arrowheads indicate the 
localization of bioSUMO1 in the nuclear membrane. (K’) and (K”) show independently the green and purple 
channels in black and white, respectively.
www.nature.com/scientificreports/
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be envisioned, such as E1 activating enzymes, E3 ligases, substrates, and pathway modulators. Caution should be 
exercised since exogenous expression of E2 or indeed any other pathway enzyme may produce non-physiological 
modifications. Additional 2A-ORFs could also be inserted to expand the number of components for specific 
needs.
We tested the incorporation of the different bioUbLs to target proteins in HEK 293FT cells. The same number 
of cells were transfected in parallel with the different bioUbL constructs and NeutrAvidin pulldowns were ana-
lysed by anti-biotin Western blot (Fig. 4B). Although the cells were not submitted to additional stress (heat-shock, 
proteasome inhibition, etc), most of the tested bioUbLs were incorporated into target proteins. As expected, the 
relative amount of conjugated proteins varied depending on the modifier. For instance, bioUb, bioNEDD8 and 
bioISG15 showed the greatest level of incorporation, with some distinct conjugates being seen for bioSUMOs and 
bioFAT10. The bioUFM1 and bioFAU incorporation was negligible. This could be due to small amount of cells/
lysate used, limiting expression levels of enzymes (E1/E2/E3) needed to incorporate the respective bioUbLs, or 
necessity of a particular stimulus to activate conjugation.
Since biotinylation occurs in vivo, we analysed the cellular distribution of the different bioUbLs by using 
fluorescent streptavidin (Fig. 4C–J). The different bioUbLs showed distinct localization patterns, suggesting 
that distribution in part may reflect localization of endogenous conjugates. Most of the UbLs are predominantly 
nuclear, although not exclusively, as seen with bioUb, bioNEDD8 or bioFAT10 (Fig. 4D,G,H). The bioSUMOs 
tested showed accumulation in nuclear bodies PML-positive, with bioSUMO1 showing further enrichment in 
the nuclear envelope (Fig. 4K); these structures are known to be enriched in SUMOylated proteins. The unique 
and characteristic patterns observed for each bioUbL suggests incorporation into a specific set of target proteins, 
further supporting the specificity of the bioUbL system.
Assessment of bioSUMOs in human cells. To further evaluate the suitability of the system in mam-
malian cells, we chose to test SUMOylation of a specific target protein. The human transcription factor SALL1 
was previously described to be SUMOylated in vitro52. By co-transfecting human SALL1 fused to YFP with bio-
SUMO1 or bioSUMO3 into HEK 293FT, we were able to confirm the SUMOylation of SALL1 in cells (Fig. 5A). 
We also observed the partial colocalization of the protein with bioSUMO1 (Fig. 5B) in a similar way than with the 
endogenous SUMO2/3 as revealed with the anti-SUMO antibodies (Fig. 5C).
PML SUMOylation is enhanced by the treatment with arsenic trioxide (ATO), triggering its polyubiquitina-
tion and subsequent degradation by the proteasome. Co-transfection of PML and bioSUMO3 was used to test 
the ATO response. As expected, after treatment we detected a decrease in the levels of unmodified PML in HEK 
293FT cells (Fig. 5D, input panels, white arrowhead). In pulldowns, the levels of biotinylated PML increased, as 
expected from an increased incorporation of bioSUMO3 provoked by ATO (Fig. 5D, elution panels, black arrow-
heads; Control lanes in input panels show endogenous SUMOylation).
Besides testing for bioSUMOylation of particular proteins, we performed a small-scale MS experiment using 
HEK 293FT cells expressing bioSUMO3 (without E2 conjugase) or BirA alone. NeutrAvidin pulldowns were sub-
jected to gel electrophoresis and stained with SYPRO-Ruby. Eleven prominent bands were excised and submitted 
for in-gel digestion and further identified by nLC MS/MS in Orbitrap. Twenty main proteins were identified in 
those bands, with all of them being previously described as SUMO targets, confirming the validity of the system 
(Fig. 5E). By Western blot analysis, we were able to observe bioSUMO3-modified forms for several of these tar-
gets, including Sirtuin 1 (SIRT1), Ran GTPase-activating protein 1 (RANGAP1), PML and Poly [ADP-ribose] 
polymerase 1 (PARP) (Fig. 5F). These experiments demonstrated that the bioSUMO system was sufficiently sensi-
tive to detect the SUMOylated fraction of these proteins without stressing the cells. Interestingly, we identified Ub 
in the pilot MS experiment (Fig. 5E) and furthermore, we detected Ub in the pulldown lane of the Western blot 
(Fig. 5F), which suggests that either multiple PTMs (independent SUMO3 and Ub) or mixed-chain formation 
(SUMO3-Ub chains) can occur on substrates.
As seen with the Drosophila bioSmt3 vector, inclusion of the SUMO E2 enzyme UBC9 in the bioSUMO vec-
tors led to a general increase the levels of modified targets. In the case of the bioNEDD8 vector, the inclusion 
of the corresponding E2 UBC12 both increased the level of modified proteins and changed the overall pattern 
(Supplementary Fig. S5). Specifically, the presence of UBC12 favours the lower molecular weight conjugates (two 
asterisks) in contrast to the higher molecular weight ones (one asterisk). Since NEDD8 overexpression has been 
reported to lead to misincorporation into non-habitual substrates by Ub pathway enzymes53, co-introduction 
of the NEDD8 E2 may suppress this effect. In addition, bioNEDDylation is drastically reduced in presence of 
MLN4924, an inhibitor of NEDD8 activating enzyme NAE1 (Supplementary Fig. S5), confirming that bioNEDD8 
is processed by the same enzymes as the endogenous NEDD8. CUL3, a known NEDDylated protein, can be cap-
tured using the bioNEDD8 vector and detected using a specific antibody (Supplementary Fig. S5).
Isolation and identification of bioUFM1 conjugates in human cells. To further test the bioUbL 
approach in mammalian cells, we chose one of the less-studied UbLs, UFM1, to enrich for potential conjugates. 
To increase the efficiency of bioUFM1-conjugation, we co-expressed UFC1, the specific E2 enzyme involved in 
UFMylation (Fig. 6A). Few UFM1-conjugated proteins have been described, but perhaps the best character-
ized was DDRGK domain-containing protein 1 (DDRGK1, also known as UFBP1)54,55. A role for DDRGK1 as a 
co-factor of UFMylation has been postulated30, and knockout mice also display defects in embryonic erythroid 
development and adult hematopoiesis56. Using co-expression in HEK 293FT cells, we validated bioUFMylation 
of DDRGK1 (Fig. 6A).
To identify potential UFMylated proteins, we performed a larger-scale experiment using the bioUFM1/
UFC1 construct in HEK 293FT cells. Since ER stress can upregulate the expression of UFM1 and UFMylation 
enzymes55, cells were treated with thapsagargin, a chemical inducer of ER stress (via inhibition of the ER Ca2+ 
ATPase pump). Neutravidin pulldowns were resolved by SDS-PAGE and analysed by MS. After normalization 
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Figure 5. Isolation and identification of bioSUMO3-conjugates in mammalian cells. (A) Western blot of 
pulldowns from HEK 293FT cells showing that the transcription factor SALL1 fused to YFP was SUMOylated 
in presence (+ ) of bioSUMO1 (lane 4) or bioSUMO3 (lane 5; bioSUMO1-BirA or bioSUMO3-BirA, 
respectively). Black arrowhead indicates the modified SALL1-YFP in the elution panel (lanes 4, 5), which is 
shifted in comparison to the non-modified SALL1-YFP in the input panel (white arrowhead, lanes 1–3).  
Molecular weight markers are shown to the left. (B,C) Partial colocalization between SALL1-YFP (green) 
and bioSUMO1 (purple) (bioSUMO1-BirA-UBC9) in U2OS cells (B) or with endogenous SUMO2/3 (C, 
purple). White arrowheads indicate colocalization. Nuclei were stained with DAPI (blue). (B’,C”) Green 
and purple channels are shown independently in black and white. (D) SUMOylation of PML by bioSUMO3 
(bioSUMO3-BirA-GP) increases after ATO treatment. bioSUMO3-modified PML (black arrowheads) can be 
detected by anti-HA Western blot in the input (upper panel, lanes 1–4) and the elution (lower panel, lanes 1–4; 
NeutrAvidin pulldown), while the level of the non-modified form of PML is reduced (input panel, lanes 1–6; 
white arrowhead). Note that modification of PML by endogenous SUMO is also visible in the input panel after 
ATO treatment (lanes 5 and 6, grey arrowheads). Control indicates cells transfected with BirA-GP. Molecular 
weight markers are shown to the left. (E) Up: schematic representation of the bioSUMO3 vector for mammalian 
cells. Left: the Western blot shows the enrichment in bioSUMO3 conjugates in the elution panel using anti-
biotin antibodies (lane 3, bracket). Arrowhead indicates free bioSUMO3. Right: bioSUMO3-modified proteins 
identified by nLC MS/MS on Orbitrap. (F) Validation of bioSUMO3-modified proteins. Specific antibodies 
against endogenous proteins were used: Ub, SIRT1, RANGAP1, PML and PARP. GAPDH is shown as a control 
in the input panel. In the elution panels, arrowheads indicate the modified forms of the respective proteins and 
the bracket indicates the ubiquitinated proteins (lanes 3). Molecular weight markers are shown to the left.
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to remove background hits and curation, we identified 82 proteins that are potential UFMylated targets (see 
Methods; Supplementary Data S4, Supplementary Fig. S6). Among these hits, we did not detect peptides from 
DDRGK1, but this could be due to low expression levels of this protein in HEK 293FT.
Figure 6. Isolation and identification of bioUFM1-conjugates in mammalian cells. (A) Up: schematic 
representation of the bioUFM1 vector for mammalian cells. Below, left: Validation of HA-DDRGK. Right, top 
twenty bioUFM1-modified proteins. (B) GO analysis for biological process, cellular component and molecular 
function of the selected bioUFM1-conjugated protein set (n = 82). (C) Validation of bioUFM1-modified 
proteins CYB5R3 and PSMB5 fused to HA tag. In the elution panels (lanes 3 and 4), black arrowheads indicate 
the modified forms of the respective proteins. Residual non-specific interactions of non-modified forms are 
indicated by white arrowheads. Molecular weight markers are shown to the left.
www.nature.com/scientificreports/
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Although UFMylation has been largely studied in the context of ER function, GO analysis showed that there 
was a significant enrichment in categories linked to RNA, such as mRNA transport (biological process) RNA, 
polyA-RNA binding (molecular function) or nucleoplasm (cellular component) (Fig. 6B; Supplementary Data S4). 
This is consistent with the observed nuclear localization of bioUFM1 in U2OS cells (Fig. 4J). The STRING anal-
ysis revealed an interconnected network of proteins, where 2 clusters were identified related with RNA splicing 
and ribonucleotide biosynthetic process (Supplementary Fig. S7, Supplementary Data S4). Of note, some proteins 
in our hit list are detected together in stable protein complexes (e.g. SLC1A5:CYB5R3, RTN4:ILF3, ILF3:SRRM2, 
PFAS:PPP6R3, SF3B1:ZNF326; DDX21:PARP1)57, or as yeast two-hybrid interactors (e.g. RTN4:SNX1)58, or as 
functional interactors (PARP1:MRE11)59,60. Since purification of bioUFM1 conjugates is under denaturing condi-
tions and non-covalent interactions via UFM1 should be non-existent, we speculate that UFMylation may occur 
on multiple members of protein complexes, as it has been shown for SUMOylation and DNA repair complexes61. 
Interestingly, ODR4 (also called C1ORF27) is a homolog of C. elegans odr4, an ER-associated transmembrane 
protein found in complex with odr8, the C. elegans orthologue of UFSP2 (UFM1-specific protease 2)62.
Out of the 82 selected proteins, 47 have been reported as targets of SUMOylation and 45 as targets of ubiq-
uitination (Supplementary Fig. S7, Supplementary Data S4). 32 are targets both of SUMOylation and ubiquitina-
tion. It is possible that these different UbL modifications might compete for the same target lysines or that they 
might take place at the same time. Peptides of Ub were also detected in the MS analysis, suggesting independent 
UFMylation and ubiquitination of the same substrate or, alternatively, the presence of UFM1-Ub mixed chains. 
Increases in scale and sensitivity are necessary to reveal the sites of UFM1 conjugation on substrates.
As expected, the co-expressed E2 UFC1 was identified. In pilot experiments that expressed only bioUFM1, 
endogenous UFC1 was identified (data not shown). Among the next 20 best-scoring bioUFM1 conjugates, we 
identified UBA5, the E1 enzyme that activates UFM1. Peptides from UFL1, the reported UFM1 E3 ligase, were 
not identified, but again could be due to expression levels and scale of the experimental setup. We found proteins 
involved in splicing and RNA trafficking (KHSRP- KH-type splicing regulatory protein, HNRNPF- heteroge-
neous nuclear ribonucleoprotein F), meiotic recombination and double-strand break (DSB) repair (MRE11A- 
MRE11 meiotic recombination 11 homolog A) and protein transport (SELENBP1- selenium binding protein 1).
We chose two MS hits to verify our results. Due to links of UFM1 to erythroid development and hemato-
poiesis, we chose cytochrome B5 reductase 3 (CYB5R3), since mutations can give rise to methemoglobinemia, 
characterized by the accumulation of blue-tinted methemoglobin in the blood, which gives the patients an unu-
sual blue-tinted skin colour. Furthermore, CYB5R3 is ER-associated, specifically on the cytoplasmic side of the 
outer ER membrane63. A second interesting hit is PSMB5, one of the core beta subunits of the 20S proteasome. 
Mutations or overexpression of PSMB5 can lead to resistance to the proteasome inhibitor bortezomib, a chem-
otherapeutic agent for multiple myeloma and mantle cell lymphoma. Using bioUFM1 and exogenous UFC1 in 
HEK 293FT cells, we were able to detect UFMylated forms of both CYB5R3 and PSMB5, even without using ER 
stress conditions (Fig. 6C). Further functional assessment of the role of UFMylation for these targets will require 
additional effort.
Taken together, the bioUFM1 approach is an efficient method for the isolation and MS identification of poten-
tial UFMylated proteins in mammalian cells, as well as for the validation of specific targets. Due to the role of 
UFMylation in erythroid development uncovered through mouse genetic studies, exploration of these targets or 
discovery of new ones could be pursued in erythroleukemic or erythroid progenitor cell lines.
Conclusions
Here we report the development of an efficient system to facilitate the study of potential UbL-modified proteins 
in both mammalian and Drosophila cells, as well as transgenic flies, that is suited for MS-based proteomics, vali-
dation and analysis of specific UbL-conjugated targets. This system represents multiple advantages with respect to 
other available UbL purification systems. The modular vectors represent a flexible platform to facilitate assembly 
of different elements into a single plasmid, even allowing in vivo biotinylation of non-UbL proteins of interest. 
Depending on the configuration, the vectors can be used for transient transfections, with FACS or drug selection 
allowing for enrichment, or for stable cell line generation. For bioUbLs, the possibility to co-express correspond-
ing E2 conjugases or E3 ligases may enhance sensitivity and perhaps enrich for specific substrates of particular 
E2s or E3s. In the studies reported here, we have co-expressed E2 conjugases in the case of bioSmt3 in cells (but 
not in flies), and in the case of bioUFM1 (but not bioSUMO3). Expression of the E2 conjugases and/or E3 ligases, 
together with the bioUbL construct, might give rise to non-physiological modifications in cells, but this approach 
might facilitate the identification of novel targets below the sensitivity of other methods, or address substrate 
preferences for particular E3s or E2/E3 combinations. The co-expression strategy has been widely used in the 
literature for various UbLs, as it can be seen in some recent examples30,64–70. With caution in mind, we could not 
find specific reports showing that exogenous UBC9 or UFC1 drives unspecific modification of substrates. Related 
to this point, no gross developmental or physiological abnormalities were observed in mice that overexpress Ubc9 
systemically, despite the overall increase in SUMOylation levels71. By overexpressing the bioUbL, we are likely 
saturating the existing endogenous E2 and only a certain amount of the bioUbL gets loaded (i.e. Lwr-bioSmt3). By 
supplying additional E2, cells will be able to make more Lwr-bioSmt3, which would lead to more SUMOylation 
and higher yield of lower abundance targets (so, more overall IDs in the MS analysis). UBC9 is involved in the 
selection of SUMO targets through its direct interaction with the SUMO consensus sites present in those targets; 
therefore, exogenous UBC9 expression might circumvent the need of E3 ligases or other stimulatory mechanisms 
(reviewed in ref. 7), but might not result in random SUMOylation of exposed lysines. However, the exogenous 
expression of E2/E3 enzymes might not reflect the physiological condition of a particular cell type/developmental 
stage/stress situation. The choice and convenience to supply exogenous E2 or not can be decided by researchers 
for their specific experimental settings, and secondary validations by complementary techniques is encouraged 
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before embarking on detailed studies. All bioUbL vectors are provided without co-expression of E2s, while some 
of them co-express E2s, so that users can choose and compare when necessary.
To compare and contrast different approaches to UbL modifications, we highlight some advantages of the 
bioUbL system. The strong binding between biotin and streptavidin allows for purification under denaturing 
conditions, which maximizes solubility of the proteome and inactivates UbL “removal” enzymes (i.e. deubiq-
uitinases, deSUMOylases, etc.). Likewise, strong binding allows high stringency washes that reduce non-specific 
background. Compared to the use of polyHis-tagged UbLs, only three endogenously biotinylated carboxylases are 
recovered as contaminants and are easily identified by MS. While antibody-based immunopurification of endoge-
nous UbL-conjugates is ideal23, specific antibodies and commercial resins do not exist for all UbLs. Regarding the 
identification of UbL modification sites, use of antibodies that recognize branched-peptide remnants after trypsin 
digestion of UbL-modified proteins have been used to identify thousands of modification sites (Ub/NEDD8/
ISG1572; modified SUMO73), but remains problematic due to expense, set-up, and specificity. Also, this approach 
is not yet available for all UbL modifications. Using SUMO as an example, identification of SUMO conjugation 
sites has been facilitated by introducing mutations close to the C-terminal di-Gly, allowing trypsin or LysC to 
generate short MS-compatible branched peptides21,74. The bioUbLs can be mutated as necessary to apply this 
strategy to SUMO and if needed, to other UbLs to facilitate conjugation site identification. In conjunction with 
antibodies to recognize an endogenous protein of interest, the bioUbLs can be used to quickly validate potential 
modifications by Western blotting. With co-expression of tagged proteins and appropriate scale-up, bioUbLs may 
also allow study of modification sites by MS, after single-step or two-step purifications. Subcellular localization of 
bioUbLs can be visualized using fluorescent streptavidin, although this application is limited in that one cannot 
distinguish between unconjugated and conjugated pools, nor localize in situ UbL modification of specific pro-
teins. The application of bioUbLs in transgenic animals (as demonstrated for bioUB in Drosophila and mice)33,34,39 
may allow tissue- or temporal-specific approaches to analyse UbL modifications. Use of the bioUbL system can 
provide either a global overview or a specific picture of the UbL modifications in most cell types and is compatible 
with drug treatments, environmental stress, and manipulations of other genes (overexpression, RNAi, CRISPR/
Cas9 knockout or activation, etc.). We envision that it will complement existing techniques based on its high 
versatility, reliability and accessibility to most laboratories.
Taken together, these features make the bioUbL system a good choice for researchers interested in UbL modi-
fications, either for validation when using proteins of interest or for explorative proteomics analysis.
Methods
Generation of vectors. All vectors (Supplementary Data S1) were based on Ac5-STABLE2-neo that 
contains three separate ORFs (Module1, Module 2, Module3; Fig. 1A) separated by 2A sequences35 (https://
www.addgene.org/32426/). A codon-optimized version of BirA (BirAopt)36 was cloned into Module 2. In some 
cases, a C-terminal V5 epitope tag was added to facilitate detection (BirAoptV5). The Bio peptide (AviTag: 
MLNDIFEAQKIEWHE)32, was fused to a degenerated Drosophila smt3 sequence resistant to RNAi (EMBL data-
base accession number FN539078)75 to generate bioSmt3, and cloned into Module 1. A cassette encoding GFP-
puromycin fusion (GFPpuro) or puromycin alone (puro) was cloned into Module 3. Additional bioUbL vectors 
were generated by substituting the smt3 sequence. To generate the mammalian vectors, the Drosophila Actin5C 
(Ac5) promoter was substituted by the composite promoter CAG76. bioUbL vectors and cloning strategies are 
summarized in Supplementary Data S1.
For the generation of CMV-SALL1-YFP, the SALL1 ORF was amplified by high-fidelity PCR and cloned 
into EcoRI-SalI sites of pEYFP-N1. For GFP-kuk, GFP-Ote and GFP-bocks, the respective genes were amplified 
with stop codons from S2R+ cDNA by high-fidelity PCR and cloned into Ac5-STABLE1-neo. In the case of 
Flag-Cherry-tsr, the GFP module in Ac5-STABLE2-neo was substituted by the Tsr ORF amplified from S2R+ 
cDNA. For HA-CYB5R3, HA-PSMB5, and DDRGK1-2xHA, ORFs were amplified by high-fidelity PCR from 
293FT or HeLa cDNA, and cloned into CB6-HA or CMV-2xHA. All vectors were checked by sequencing.
Isolation of biotinylated substrates in mammalian and Drosophila cells. HEK 293FT cells (human 
embryonic kidney; Invitrogen) were maintained at 37 °C in DMEM (Dulbecco’s modified Eagle’s medium; Gibco) 
supplemented with 10% FBS, 1% penicillin/streptomycin (GIBCO). Transient transfections were performed 
using the calcium phosphate method in complete medium supplemented with biotin (50 μ M). Cells were har-
vested 48–72 hours after transfection. For the isolation of bioSUMO3-conjugates coupled with MS, 10 × 10 cm 
dishes were transfected with bioSUMO3-GP or FC-GP as control. For the isolation of UFM1-conjugates coupled 
with LC-MS, 10 × 10 cm dishes were transfected with bioUFM1-UFC1 or BirA-puro.
Drosophila S2R+ cells were obtained from DGRC (https://dgrc.cgb.indiana.edu) and cultured at 25 °C in 
Drosophila Schneider’s medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (Gibco) 
and 1% penicillin/streptomycin (Gibco). Transfections were performed using calcium phosphate in 5 × 10 cm 
dishes with 2 μ g of pAC5-Gal4 (Addgene #24344), and 8 μ g of Ac510x-bioSmt3-Lwr or Ac510x-FC-Lwr in com-
plete medium supplemented with 50 μ M biotin.
Transfected cells were collected after 48–72 hours (HEK 293FT) or 72–96 hours (S2R+ ), washed with 
phosphate buffered saline (PBS) and resuspended in lysis buffer [0.5 ml/10 cm dish; 8 M urea, 1% SDS, 50 mM 
N-ethylmaleimide, 1× protease inhibitor cocktail (Roche) in PBS]. Sonication was performed as needed to reduce 
sample viscosity. To reduce urea concentration, the samples were diluted by adding binding buffer (3 M urea, 
1 M NaCl, 0.25% SDS; 0.5 volume for HEK 293FT, or 3 volumes for S2R+). Incubation was done using 100 μ l 
suspension of high-capacity NeutrAvidin-agarose beads (Thermo Scientific) overnight at room temperature (RT). 
Washes were done according to Franco et al.33: 2× WB1, 3× WB2, 1× WB3, 3× WB4, 1× WB1, 1× WB5 and 
3× WB6 [WB1: 8 M urea, 0.25% SDS in PBS; WB2: 6 M guanidine hydrochloride in PBS; WB3: 6.4 M urea, 1 M 
NaCl, 0.2% SDS in PBS (pre-warmed to 37 °C); WB4: 4 M urea, 1 M NaCl, 10% isopropanol, 10% ethanol, 0.2% 
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SDS in PBS; WB5: 8 M urea, 1% SDS in PBS; WB6: 2% SDS in PBS]. Samples were eluted in 100 μ l of 4× Laemmli 
sample buffer with 100 mM DTT by two cycles of heating (5 minutes; 99 °C), with vortexing in between. For MS 
analysis, the bead slurry was transferred to a Vivaclear Mini 0.8 μ m PES filter (Sartorius) and spun to recover 
bead-free eluate.
Isolation of biotinylated substrates in vivo. Flies were raised at 25 °C on standard Drosophila medium 
supplemented with biotin (50 μ M). Strains: w;pUAS-BirA33; w;UAS-Smt3i50; y1w*;P{Gal4-Hsp70.PB}31-1/ 
CyO;TM6B,Tb+ (called here hs-Gal4), Bloomington Drosophila Stock Center, BDSC#1822; w;phm-Gal4, 
UAS-mCD8::GFP/TM6B, Tb (called here phm-Gal4)77; w;UAS-nls-eGFP/CyO (BDSC #4775); Information about 
other strains can be found in FlyBase (http://flybase.bio.indiana.edu). The plasmid pJFRC81-bioSmt3 (backbone: 
Addgene #36432) was used for generating transgenic flies (BestGene).
Crosses between w;UAS-Smt3i,p-bioSmt3 and phm-Gal4 were performed at 25 °C. Crosses with hs-Gal4 were 
done at 25 °C and w;UAS-Smt3i/+;p-bioSmt3/hs-Gal4 larvae were selected at L2 instar. As controls, we used 
w; UAS-Smt3i/+;pUAS-BirA/hs-Gal4 larvae. Approximately 200 larvae were collected per condition and three 
heat shock events were performed at 37 °C during 30 minutes each. Dissections were performed in cold PBS and 
the lysis was done by using 1 ml of lysis buffer [8 M urea, 1% SDS, 50 mM N-ethylmaleimide in PBS and protease 
inhibitor mixture (Roche)]. Larval tissues were homogenized, sonicated, and after clearing by centrifugation at 
4 °C, the supernatants were used for NeutrAvidin pulldowns performed as described above for Drosophila cells 
using 100 μ l of suspension beads, using the same binding buffer dilution and washing/elution protocol.
Mass Spectrometry. Pulldown elutions were separated by SDS-PAGE and stained with Brilliant Blue 
G-Colloidal Concentrate (Sigma) according to manufacturer’s instructions. Gel bands were excised from the 
whole gel lane, destained and proteins were in-gel digested with trypsin (sequencing grade, Promega) overnight 
as previously described78. The resulting peptide mixtures were extracted, desalted, and concentrated prior to 
online nanoLC-MS/MS analysis using and EASY nLC1000 system (Proxeon) connected to a Q-Exactive orbitrap 
(Thermo Scientific) through a nanoelectrospray ion source79. All raw LC-MS files were processed with MaxQuant 
software (version 1.4.0.3, www.maxquant.org) and search against species-specific Uniprot protein sequence data-
bases and common contaminants using the Andromeda peptide search engine with a false discovery rate of 
0.01 at both peptide and protein level. In the case of bioSUMO3, a nano Acquity (Waters) coupled on-line to an 
Orbitrap-XL (ThermoFisher) was used. Orbitrap raw MS files were processed with Proteome Discoverer (version 
1.2) and searched with Mascot (Matrix Science).
The lists of proteins identified by MS were analysed as follows. First, contaminants and proteins identified by 
only one peptide were eliminated. Then, only those proteins with at least four-fold higher iBAQ values (label-free 
intensity-based absolute protein quantification) in the experiment samples versus the controls were considered 
as positive hits. Calculation was done taking into account a baseline for the control, which corresponds to the 
minimum iBAQ values registered in each control of every experiment.
Significantly enriched Gene Ontology annotation terms were determined using VLAD (http://proto.
informatics.jax.org/prototypes/vlad-1.0.3/), InnateDB80 and G:profiler81. Graphical representation in 
Supplementary Figs S2, S3 and S6 was done using Prism GraphPad and eulerApe v382. Network association 
analysis was done using STRING database83 and analysed using Cytoscape MCODE clusters and Cluster maker 
Visualizations84,85.
Western Blotting. Input, flowthrough (FT) and elution samples were collected at different steps of the pull-
down protocol. Elution samples were prepared as described above. Input and FT samples were adjusted to 4× 
Laemmli buffer. After boiling, proteins were separated by SDS-PAGE (BioRad) and blotted using wet transfer to 
PVDF membranes (Millipore). Membranes were blocked in 1× PBS with 0.1% Tween-20 (PBS-T) and 5% non-fat 
dry milk for 1 hour. When anti-biotin antibody was used, 1× Casein Blocking Buffer in PBS (Sigma #B6429) 
was used. Primary antibodies were used in blocking buffer (1 hour at RT, or overnight at 4 °C) as follows: mouse 
monoclonal anti-Usp (1:200)86; mouse monoclonal anti-Osa (1:50, DSHB); mouse monoclonal anti-Lamin Dm0 
(1:500, DSHB #ADL84.12); rabbit polyclonal anti-Fax (1:1000)87; rabbit polyclonal anti-eIF4E (1:1000)88; rab-
bit polyclonal anti-SIRT1 (1:1000, Cell Signaling Technology #D739); mouse monoclonal anti-RanGAP1C-5 
(1:1000, SantaCruz #sc-28322); rabbit polyclonal anti-PARP (1:1000, Cell Signaling Technology #9542); rabbit 
polyclonal anti-PML (1:1000, Bethyl Laboratories); rabbit polyclonal anti-Ub (1:1000, Sigma #U5379); rabbit pol-
yclonal anti-Cullin 3 (1:1000, Cell Signaling Technology #2759); mouse monoclonal anti-Flag M2 (1:1000, Sigma 
#F3165); mouse monoclonal anti-GFP (1:1000, Roche #11814460001); mouse monoclonal anti-HA (1:1000, 
Sigma #H3663); mouse monoclonal anti-actin AC-74 (1:5000, Sigma #A2228); HRP conjugated anti-biotin 
(1:1000, Cell Signaling Technology #7075); HRP conjugated anti-tubulin (1:5000, Proteintech #66031); HRP 
conjugated anti-GAPDH (1:5000, Proteintech #60004).
After three washes with PBS-T, blots were incubated for one hour in blocking buffer with secondary anti-
bodies: HRP-conjugated anti-mouse (1:5000, Jackson ImmunoResearch); HRP-conjugated anti-rabbit (1:5000, 
Jackson ImmunoResearch). Membranes were washed again three times in PBS-T and then developed using 
chemiluminescence with Clarity Western ECL substrate (Bio-Rad) or SuperSignal West Femto substrate 
(Thermo).
Immunostainings. Drosophila S2R+ cells were transfected with calcium phosphate in 6 well-plates using 
2 μ g of pAc5-bioSmt3-GP or pAC5-Gal4 (Addgene #24344). After 3 days, cells were placed on coverslips treated 
with concanavalin A (Sigma) and, once attached (4 hours), fixation was performed with 4% paraformaldehyde 
followed by permeabilization with 0.1% Triton X-100 in 1x PBS.
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Drosophila larvae were dissected in 1x PBS and fixed for 20 minutes in 4% paraformaldehyde, washed three 
times in PBT (PBS, 0.3% Triton X-100) for 20 minutes, and blocked in PBT + 1% BSA for one hour.
U2OS cells were plated directly in 24-well plates with acid-washed coverslips and transfected using jetPEI 
(Polyplus) or Effectene (Qiagen) according to the manufacturer’s instructions. For the localization of different 
bioUbLs, 1 μ g of bioUbL-GP or 1 μ g of BirA-puro as control were used; for the localization of SALL1, 750 ng of 
CMV-SALL1-YFP and 250 ng of bioSUMO1-2A-BirA-2A-UBC9 were used.
Antibodies and dyes: DAPI to label nuclei (1:15000, Sigma); Alexa Fluor 594 conjugated-streptavidin (1:200, 
Jackson ImmunoResearch) to visualize biotinylated proteins; mouse monoclonal anti-GFP (1:500, Roche); rabbit 
polyclonal anti-Smt3 (1:150)89; rabbit polyclonal anti-SUMO2/3 (1:100, Eurogentec #AV-SM23-0100). Secondary 
antibodies: anti-rabbit Alexa-568, anti-mouse Alexa-488 and anti-rabbit Alexa-488 (1:200, Molecular Probes). 
Samples were mounted in Prolong Gold antifade reagent (Molecular Probes). Confocal images were taken with a 
Leica DM IRE2 confocal microscope and images were processed using Adobe Photoshop CS5 software.
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